Tricalcium phosphate
Based on 1 Customer Validation
Tricalcium phosphate is a calcium-phosphorus compound mainly composed of calcium ions and phosphate (PO43-). Tricalcium phosphate promotes osteogenic differentiation, inhibits adipogenic and chondrogenic differentiation, and serves as a scaffold for spinal fusion implants. Tricalcium phosphate supports reparative dentin formation, mineralized nodule formation, and calcium ion release. Tricalcium phosphate is commonly used in fields such as biomaterials, bone repair, food additives, and pharmaceutical preparations.
For research use only. We do not sell to patients.
- Purity: 98.00%
- CAS No.: 7758-87-4
- Formula: Ca3(PO4)2
- Molecular Weight:310.18
-
Storage:Powder -20°C, 3 years , 4°C, 2 years ; In solvent -80°C, 6 months , -20°C, 1 month
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Biological Activity
-
Chemical Information
- Purity & Documentation
- References
-
Help & FAQs
-
HY-W243408D
Calcium carbonate, for cell culture -
HY-21170B
Trifluoromethanesulfonate lithium -
HY-B2242
Calcium phosphate -
HY-Y1054
Magnesium stearate -
HY-W011727A
Pyridoxal 5'-phosphate monohydrate -
HY-Y0332B
Potassium dihydrogen phosphate, AR,99.5% -
HY-Y0332K
Potassium dihydrogen phosphate, for cell culture -
HY-Y0308E
Sodium phosphate dibasic, for cell culture -
HY-Y1267D
Magnesium sulfate, for cell culture -
HY-Y1267
Magnesium sulfate -
HY-Y0308
Disodium phosphate
Biological Activity
Description
In Vitro
Tricalcium phosphate (5 mg/mL; 8-25 days) increase ALP activity, a marker of osteogenic differentiation, in hBMSCs by 1.4-fold after 8 days and 2.2-fold after 25 days[2].
Tricalcium phosphate (5 mg/mL; 8 days) induce osteogenic gene expression in hBMSCs, increasing Runx2 by 2.3-fold and BMP2 by 4.7-fold after 8 days[2].
Tricalcium phosphate (10-20%; 4, 7, 10 days) conditioned medium from light-cured composites causes human dental pulp stem cells to exhibit comparable mineralized nodule formation to each other, with lower mineralization than controls under differentiation conditions on day 10[3].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
In Vivo
Tricalcium phosphate (5 mg/mL; added to hBMSC culture media; 8 days; surgically implanted; single administration) scaffold combined with untreated hBMSCs supports spinal fusion in immunodeficient rats, achieving 75% fusion with 0.5% bone surface area in fusion mass after 8 weeks[2].
Tricalcium phosphate (10%; local application; light-cured for 40 s) resolves pulp inflammation by week 3 and supports moderate to abundant mineralized tissue formation by weeks 3 and 6, respectively, in Wistar rats with exposed dental pulp[3].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
Clinical Trial
| NCT Number | Sponsor | Condition | Start Date |
Phase
|
|---|---|---|---|---|
| NCT01329991 | Plexxikon| | 2011-05 | PHASE1 |
Chemical Information
-
CAS No. 7758-87-4
-
Appearance Solid
-
Molecular Weight 310.18
-
Formula Ca3(PO4)2
-
Color White to off-white
-
SMILES
[Ca3(PO4)2]
-
Shipping
Room temperature in continental US; may vary elsewhere.
-
Storage
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month
Purity & Documentation
-
Data Sheet (281 KB)
-
SDS (393 KB)
- English - EN (393 KB)
- Français - FR (393 KB)
- Deutsch - DE (393 KB)
- Norwegian - NO (393 KB)
- Español - ES (393 KB)
- Swedish - SV (393 KB)
- Italian - IT (393 KB)
- Korean - KR (393 KB)
- Portuguese - PT (393 KB)
-
Handling Instructions (2659 KB)
References
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
Tricalcium phosphate Related Classifications
HY-D0833 Related Classifications
Powered by Bioz